Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company
Previously, the use of the drug was limited to patients requiring hospitalization
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Subscribe To Our Newsletter & Stay Updated
